Blueprint Medicines Corporation
BPMC
Clasificación en acciones
#2347
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Precio por acción
$129.46
Última sincronización: 2025-07-18
Capitalización bursátil
$8.36B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Blueprint Medicines Corporation (BPMC)
Categoría
Healthcare
Ganancias de Blueprint Medicines Corporation (BPMC)
Ganancias en Mar 2025 TTM: $-153.89M
Secondo gli ultimi rapporti finanziari di Blueprint Medicines Corporation, gli utili attuali della società sono $-153.89M. Nel 2023, la società ha registrato un utile di $-506.02M, un aumento con respecto a agli utili del 2022, che erano di $-552.28M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Blueprint Medicines Corporation desde 2013 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-153.89M | 133.66% |
| 2024 | $-65.86M | -86.98% |
| 2023 | $-506.02M | -8.38% |
| 2022 | $-552.28M | -13.85% |
| 2021 | $-641.08M | -303.56% |
| 2020 | $314.94M | -190.58% |
| 2019 | $-347.69M | 46.93% |
| 2018 | $-236.64M | 59.76% |
| 2017 | $-148.12M | 104.32% |
| 2016 | $-72.50M | 37.38% |
| 2015 | $-52.77M | 30.99% |
| 2014 | $-40.29M | 92.64% |
| 2013 | $-20.91M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -3,527.62% |
US
|
|
| $-3.09B | 1,905.93% |
US
|
|
| $-4.02B | 2,509.72% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,367.53% |
NL
|
